Richard Burr: “I would not call that an investigation. I would call it a whitewash.”

Where is that money gone? How is it being spent? Where is it obligated?

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

He is an embarrassment on any day that ends in Y.

The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.